Metastatic Prostate Cancer - Pipeline Review, H1 2013


#164526

75pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Metastatic Prostate Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer. 

Metastatic Prostate Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Prostate Cancer.
  • A review of the Metastatic Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Prostate Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Metastatic Prostate Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Metastatic Prostate Cancer 9
Metastatic Prostate Cancer Therapeutics under Development by Companies 11
Metastatic Prostate Cancer Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Metastatic Prostate Cancer Therapeutics - Products under Development by Companies 18
Companies Involved in Metastatic Prostate Cancer Therapeutics Development 19
Sanofi-Aventis 19
Bavarian Nordic A/S 20
Sun Pharmaceutical Industries Limited 21
ValiRx Plc 22
Marshall Edwards, Inc. 23
Osta Biotechnologies Inc. 24
Regeneron Pharmaceuticals, Inc. 25
Colby Pharmaceutical Company 26
Actinium Pharmaceuticals, Inc. 27
Alethia Biotherapeutics Inc. 28
NewLink Genetics Corporation 29
Metastatic Prostate Cancer - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
pracinostat - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AB-16B5 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CPC-410 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
veliparib - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VAL-201 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
sirolimus + [docetaxel] + [prednisone] - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
aflibercept + [docetaxel] + [prednisone] - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
samarium Sm 153 lexidronam pentasodium - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
cabazitaxel - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
OB-24 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
aflibercept - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
NLG-8189 + [docetaxel] - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Actimab-P - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
rilimogene galvacirepvec + [ipilimumab] - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
MEDI-6469 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
LU-901 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
leuprolide acetate - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Compound-46 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
KBU-2046 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
DT-310 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Metastatic Prostate Cancer Therapeutics - Drug Profile Updates 62
Metastatic Prostate Cancer Therapeutics - Discontinued Products 68
Metastatic Prostate Cancer Therapeutics - Dormant Products 69
Metastatic Prostate Cancer - Product Development Milestones 71
Featured News & Press Releases 71
Jun 27, 2012: Astellas Pharma And Medivation Announce European Regulatory Submission For Enzalutamide For Treatment Of Prostate Cancer 71
Jun 02, 2012: Zytiga's Phase III Results Show Significant Improvement In Radiographic Progression-Free Survival And Trend For Increased Overall Survival In Metastatic Prostate Cancer Patients 71
May 16, 2012: J&J's ZYTIGA Now Available For Eligible Patients In Nova Scotia, Newfoundland And Labrador For Prostate Cancer 72
Feb 24, 2012: Active Biotech And Ipsen Report Tasquinimod Phase II Long Term Safety Data At 27th European Association Of Urology Congress 72

Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

Number of Products Under Development for Metastatic Prostate Cancer, H1 2013 9
Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H1 2013 10
Number of Products under Development by Companies, H1 2013 12
Number of Products under Investigation by Universities/Institutes, H1 2013 13
Comparative Analysis by Late Stage Development, H1 2013 14
Comparative Analysis by Mid Clinical Stage Development, H1 2013 15
Comparative Analysis by Early Clinical Stage Development, H1 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 17
Products under Development by Companies, H1 2013 18
Sanofi-Aventis, H1 2013 19
Bavarian Nordic A/S, H1 2013 20
Sun Pharmaceutical Industries Limited, H1 2013 21
ValiRx Plc, H1 2013 22
Marshall Edwards, Inc., H1 2013 23
Osta Biotechnologies Inc., H1 2013 24
Regeneron Pharmaceuticals, Inc., H1 2013 25
Colby Pharmaceutical Company, H1 2013 26
Actinium Pharmaceuticals, Inc., H1 2013 27
Alethia Biotherapeutics Inc., H1 2013 28
NewLink Genetics Corporation, H1 2013 29
Assessment by Monotherapy Products, H1 2013 30
Assessment by Combination Products, H1 2013 31
Assessment by Stage and Route of Administration, H1 2013 33
Assessment by Stage and Molecule Type, H1 2013 35
Metastatic Prostate Cancer Therapeutics - Drug Profile Updates 62
Metastatic Prostate Cancer Therapeutics - Discontinued Products 68
Metastatic Prostate Cancer Therapeutics - Dormant Products 69
Metastatic Prostate Cancer Therapeutics - Dormant Products (Contd..1) 70
Number of Products under Development for Metastatic Prostate Cancer, H1 2013 9
Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H1 2013 10
Products under Development by Companies, H1 2013 11
Products under Investigation by Universities/Institutes, H1 2013 13
Late Stage Products, H1 2013 14
Mid Clinical Stage Products, H1 2013 15
Early Clinical Stage Products, H1 2013 16
Discovery and Pre-Clinical Stage Products, H1 2013 17
Assessment by Monotherapy Products, H1 2013 30
Assessment by Combination Products, H1 2013 31
Assessment by Route of Administration, H1 2013 32
Assessment by Stage and Route of Administration, H1 2013 33
Assessment by Molecule Type, H1 2013 34
Assessment by Stage and Molecule Type, H1 2013 35